CellSeed Inc. (7776.T)
Tokyo · JPY · Healthcare · Biotechnology
¥191 (+0.53%) as of
Key statistics
- Market cap
- 7.53B
- EPS (TTM)
- -28.97
- Dividend yield
- 0.00%
- 52-week range
- 175.00 – 444.00
- Beta
- 1.21
- Revenue (TTM)
- 161M
- Profit margin
- 0.00%
- Volume
- 108.10k
About CellSeed Inc.
CellSeed Inc. engages in the cell sheet regenerative medicine business in Japan, the rest of Asia, and Europe. It operates through Regenerative Medicine Support Business and Cell Sheet Regenerative Medicine Business segments. The company is involved in commercializing regenerative medicine using cell sheets, which include autologous and allogeneic chondrocyte sheets. It also offers regenerative medicine contract services comprising contract development and manufacturing; contract manufacturing and consulting for specified cell-based products; and training and education in cell culturing technology services. In addition, the company provides UpCell, a temperature-responsive cell cultureware for cell sheet engineering; RepCell, a temperature-responsive cell cultureware for cell collection; HydroCell, a low cell binding cultureware; ThermoPlate III, a heating element made of a transparent glass plate; cellZscope, an automated cell monitoring system; and cell sheet support products. CellSeed Inc. was incorporated in 2001 and is headquartered in Koto, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Koto, Japan
- Employees
- 44
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.